tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Jiangsu Recbio’s Novel HPV Vaccine Trial Approved in China

Story Highlights
Jiangsu Recbio’s Novel HPV Vaccine Trial Approved in China

Elevate Your Investing Strategy:

Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) just unveiled an update.

Jiangsu Recbio Technology Co., Ltd. announced the acceptance of its application for a clinical trial of its new HPV 9-valent vaccine, REC604c, by the National Medical Products Administration in China. The REC604c vaccine, enhanced with a novel adjuvant developed in-house, seeks to reduce vaccination doses while boosting immunogenicity and cross-protection. This development targets the male market, acknowledging the global trend of including adolescent males in HPV vaccination programs. The potential market in China is significant, with over 300 million eligible males, but success is not guaranteed.

More about Jiangsu Recbio Technology Co., Ltd. Class H

Jiangsu Recbio Technology Co., Ltd. is a biotechnology company based in China, focusing on the development of innovative vaccines. The company specializes in recombinant vaccines, targeting markets for various age groups and genders.

YTD Price Performance: -8.63%

Average Trading Volume: 31,379

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$3.96B

Find detailed analytics on 2179 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1